GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that